Publications

  1. Edwards RP, Georgescu HI, Evans. Enhanced endocytosis in aging chondrocytes. Experimental Gerontology, 19:185-189, 1984.
  2. Kelley JL, Edwards RP, Wozney P, Vaccarello L, Laifer S. Magnetic resonance imaging to diagnose a Muellerian anomaly during pregnancy. Obstet Gynecol, 75(3):521-523, 1990.
  3. Aubel S, Wozney P, and Edwards RP. MRI of female uterine and juxta-uterine masses: Clinical application in 25 patients. Magnetic Resonance Imaging, 9:485-491, 1991.
  4. Alvarez RD, Helm CW, Edwards RP, Naumann RW, Partridge EE, Shingleton HM, McGee JA, Hall JB, Higgins RV, Malone JM. Prospective Randomized Trial of LLETZ versus laser ablation in patients with cervical intraepithelial neoplasia. Gynecol Oncol 52:175-179, 1994.
  5. Naumann RW, Bell MC, Alvarez RD, Edwards RP, et al. LLETZ is an acceptable alternative to diagnostic cold-knife conization. Gynecol Oncol 55:224-228, 1994.
  6. Price FV, Kelley JL, Edwards RP. Informed consent, cancer, and truth in prognosis [letter; comment]. NEJM 331:811, 1994.
  7. Bell MC, Edwards RP, Partridge EE, Kuykendall K, Conner W, Gore H, Turbat-Herrara E and Crowley-Nowick PA. CD8+ T-lymphocytes are recruited to the neoplastic cervix. Journal of Clinical Immunology 15:130-136, 1995.
  8. Price FV, Kelley JL, Edwards RP, Hasley PB, and Amin RM. A survey of blood transfusion practices of gynecologic oncologists. Gynecol Oncol 59:45-50, 1995.
  9. Edwards RP, Kuykendall K, Crowley-Nowick PA, Partridge EE, Shingleton HM, Mestecky J. T lymphocytes infiltrating advanced grades of cervical neoplasia: CD8-positive cells are recruited to invasion. Cancer 76:1411-5, 1995.
  10. Crowley-Nowick PA, Bell M, Edwards RP, McCallister D, Gore H, Kanbour-Shakir A, Mestecky J, and Partridge EE. Normal uterine cervix: Characterization of isolated lymphocyte phenotypes and immunoglobulin secretion. Am J of Reprod Immun 34:241-247, 1995.
  11. Edwards RP, Pitts A, Crowley-Nowick PA, Partridge EE, Gore H, Mestecky J. Immunoglobulin-containing plasma cells recruited to cervical neoplasia. Obstet Gynecol 87:520-526, 1996.
  12. Kanbour-Shakir A, Kounelis S, Papadaki H, Raptis S, Edwards RP, Kelley JL, Price F, Bakker A, Swalsky PA, Przygodzki R and Finkelstein SD. Relationship of p53 genotype to second-look recurrence and survival in ovarian epithelial malignancy. Molecular Diagnosis 1:121-129, 1996.
  13. Rabinowich H, Suminami Y, Reichert TE, Crowley-Nowick PA, Bell M, Edwards RP and Whiteside TL. Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer 68:276-84, 1996.
  14. Kowalski LD, Kanbour AI, Price FV, Finkelstein SD, Christopherson WA, Seski JC, Naus GJ, Burnham JA, Kanbour-Shakir A, Edwards RP. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma. Cancer 79:1587-1594, 1997.
  15. Crowley-Nowick PA, Bell MC, Brockwell R, Edwards RP, Chen S, Partridge EE, Mestecky J. Rectal immunization for induction of specific antibody in the genital tract of women. J Clin Immun 17:370-379, 1997.
  16. Edwards RP, Gooding W, Lembersky BC, Colonello K, Hammond R, Paradise C, Kunschner AJ, Seski JC, Baldisseri M, Kirkwood JM, and Herberman RB. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after Platinum: 24 hour versus 7 day infusion. J Clin Oncol 15:3399-3407, 1997.
  17. Price FV, Edwards RP, Kelley JK, Kunschner AJ, and Hart L. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: Preliminary report. Semin Oncol 24: S15-78 - S15-82, 1997.
  18. Black CA, Cost MR, Edwards RP. Vaginally derived IgG subclasses are skewed toward non-complement fixing IgG2 and IgG4 versus serum. AJRI 39:297, 1998.
  19. Hildesheim A, Bratti C, Edwards RP, Schiffman M, Rodriguez AC, Herrero R, Alfaro M, Morera LAA, Ermatinger SV, Miller BT, Crowley-Nowick PA. Collection of cervical secretions does not adversely affect Pap smears taken immediately afterward. Clinical and Diagnostic Laboratory Immunology 5:491-493, 1998.
  20. Faul C, Miramow D, Gerszten K, Huang, C and Edwards RP. Isolated local recurrence in carcinoma of the vulva: prognosis and implications for treatment. Int J Gynecol Cancer 8:409-414, 1998.
  21. Rohan LC, Edwards RP, Kelly LA, Colonello KA, Bowman FP and Crowley-Nowick PA. Optimization of the Weck-Cel collection method for quantitation of cytokines in mucosal secretions. Clinical and Diagnostic Laboratory Immunology 7:45-48, 2000.
  22. The ASCUS-LSIL Triage Study (ALTS) Group (Edwards RP). Human Papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: Baseline data from a randomized trial. J Natl Cancer Inst 92:397-402, 2000.
  23. Vallejo MC, Edwards RP, Shannon KT, Kaul B, Finegold H, Morrison HL and Ramanathan S. Improved bowel function after gynecologic surgery with epidural bupivacaine-fentanyl than bupivacaine-morphine infusion. Can J Anesth 47:406-411, 2000.
  24. Hardesty LA, Sumkin JH, Nath ME, Edwards RP, Price FV, Chang TS, Johns CM and Kelley JL. Use of preoperative MR imaging in the management of endometrial carcinoma: Cost Analysis. Radiology 215:45-49, 2000.
  25. Faul C, Gerszten K, Edwards R, Land S, D’Angelo G, Kelley J, and Price F. A Phase I/II study of hypofractionated whole abdominal radiation therapy in patients with chemoresistant ovarian carcinoma: Karnofsky score determines treatment outcome. Int J Radiation Oncology Biol Phys 47:749-754, 2000.
  26. Sit ASY, Price FV, Kelley JL, Comerci JC, Kunschner AJ, Kanbour-Shakir A, Edwards RP. Chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecol Oncol 79:196-200, 2000.
  27. Black CA, Rohan LC, Cost M, Watkins S, Draviam R, Alber S, Edwards RP. Vaginal mucosa serves as an inductive site for tolerance. The Journal of Immunology 165:5077-5083, 2000.
  28. Hardesty LA, Sumkin JH, Nath ME, Edwards RP, Price FV, Chang TS, Johns CM, Kelley JL. Use of preoperative MR imaging in the management of endometrial carcinoma: cost analysis. Radiology; 215:45-49, 2000.
  29. Makhija S, Howden N, Edwards RP, Kelley J, Townsend DW, Meltzer CC. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: A retrospective review. Gynecol Oncol 85:53-58, 2002.
  30. Castle PE, Hildesheim A, Bowman FP, Strickler HD, Walker JL, Pustilnik T, Edwards RP, Crowley-Nowick PA. Cervical concentrations of interleukin-10 and Interleukin-12 do not correlate with plasma levels. J Clin Immunol 22(1):23-27, 2002.
  31. Lokshin AE, Kalinski P, Sassi R, Mailliard RB, Muller-Berghaus J, Storkus WJ, Peng X, Marrangoni AM, Edwards RP, Gorelik E. Differential regulation of maturation and apoptosis of human monocyte-derived dendritic cells mediated by MCH class II. Int Immunol 2002; 14(9):1027-1037.
  32. Ravin AJ, Edwards RP, Krohn MA, Kelley JR, Christopherson WA, Roberts JM. The Factor V Leiden mutation and the risk of venous thromboembolism in gynecologic oncology patients. Obstet Gynecol2002;100(6):1285-1289.
  33. Kuss I, Rabinowich H, Gooding W, Edwards R, Whiteside TL. Expression of zeta in T cells prior to interleukin-2 therapy as a predictor of response and survival in patients with ovarian carcinoma. Cancer Biotherapy & Radiopharmaceuticals. 2002;17(6):631-640.
  34. The ASCUS-LSIL Triage Study (ALTS) Group (Edwards RP). Effects of Age and Human Papilloma Viral Load on Colposcopy Triage: Data from the Randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study. J Natl Cancer Inst 2002;94:102-107.
  35. Siervo-Sassi RR, Marrangoni AM, Feng X, Naoumova N, Winans M, Edwards RP, Lokshin A. Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines. Cancer Letters 2003;190(1):61-72.
  36. Edwards RP. New treatments for ovarian cancer: Hyperthermic perfusion of peritoneal therapy. Louisville Medicine 2003;50(12):465.
  37. Makhija S, Sit A, Edwards RP, Aufman K, Weiss H, Kanbour-Shakir A, Gooding W, D’Angelo G, Ferrell R, Raja S, Godfrey E. Identification of genetic alterations related to chemoresistance in epithelial ovarian cancer. Gynecol Oncol 2003;90(1):3-9.
  38. Heron DE, Gerszten K, Selvaraj RN, King GC, Sonnik D, Gallion H, Comerci J, Edwards RP, Wu A, Andrade RS, Kalnicki S. Conventional 3D conformal versus intensity-modulated radiotherapy for the adjuvant treatment of gynecologic malignancies: A comparative dosimetric study of dose-volume histograms. Gynecol Oncol 2003;91:39-45.
  39. The ASCUS-LSIL Triage Study (ALTS) Group (Edwards RP). Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188(6):1383-1392.
  40. The ASCUS-LSIL Triage Study (ALTS) Group (Edwards RP). A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003;188(6):1393-1400.
  41. The ASCUS-LSIL Triage Study (ALTS) Group (Edwards RP). Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: A two-year prospective study.  Am J Obstet Gynecol 2003;188(6):1401-1405.
  42. The ASCUS-LSIL Triage Study (ALTS) Group (Edwards RP). Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy.  Am J Obstet Gynecol 2003;188(6):1406-1412.
  43. Sit AS, Kelley JL, Gallion HH, Kunschner AJ, Edwards RP. Paclitaxel and carboplatin for recurrent or persistent cancer of the cervix. Cancer Investigation 2004;22:1-6.
  44. Taylor DD, Edwards RP, Case CR, Gercel-Taylor C. Modulation of CD3-zeta as a marker of clinical response to IL-2 therapy in ovarian cancer patients. Gynecol Oncol 2004;94:54-60.
  45. Gordon AN, Schultes BC, Gallion H, Edwards RP, Whiteside TL, Cermak JM, Nicodemus CF. CA125 and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol 2004;94:340-351.
  46. Ault KA, Giuliano AR, Edwards RP, Tamms G, Kim LL, Smith JF, Jansen KU, Allende M, Taddeo FJ, Skulsky DM, Barr E. A Phase I Study to Evaluate a Human Papillomavirus (HPV) Type 18 L1 VLP Vaccine. Vaccine 2004;22:3004-3007.
  47. Gorelik E, Edwards RP, Feng X, Marrangoni AM, Grandis JR, Drenning SD, Velikokhatnaya L, Kwon JA, Lokshin A. IL-12 Receptor-Mediated Up-regulation of FasL in Human Ovarian Carcinoma Cells. Int J Cancer 2004, 112:620-7.
  48. Warrino DE, Olson WC, Knapp WT, Scarrow MI, Brennan LJ, Guido RS, Edwards RP, KastWM, Storkus WJ. Variance in functional CD4+T cell responses against Pan-DR presented HPV-16 E7 epitopes based on disease-stage and epitope analyzed. Cancer Research, Vol 10, 3301-3308, May 15, 2004.
  49. The ASCUS-LSIL Triage Study (ALTS) Group (Edwards RP). Interlaboratory Reliability of Hybrid Capture 2. Am J Clin Pathol. 2004 August;122(2):238-45.
  50. The ASCUS-LSIL Triage Study (ALTS) Group (Edwards RP). Colposcopy quality control by remote review of digitized colposcopic images. Am J Obstet Gynecol. 2004 Dec;191(6):1934-41.
  51. The ASCUS-LSIL Triage Study (ALTS) Group (Edwards RP). A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl cancer Inst. 2005 Jan 19;97(2):147-50.
  52. The ASCUS-LSIL Triage Study (ALTS) Group (Edwards RP). Does the interval between papanicolaou tests influence the quality of cytology? Cancer 2005 June 25;105(3):133-8.
  53. The ASCUS-LSIL Triage Study (ALTS) Group (Edwards RP). Interobserver agreement for colposcopy quality control using digitized colposcopic images during the ALTS trial. J Low Genit Tract Dis. 2005 Jan;9(1):29-35.
  54. The ASCUS-LSIL Triage Study (ALTS) Group (Edwards RP). Smoking is a risk factor for cervical intraepithelial neoplasia 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology. Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1165-70.
  55. The ASCUS-LSIL Triage Study (ALTS) Group (Edwards RP). Determinants of human papillomavirus-negative, low-grade squamous intraepithelial lesions I the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions triage study (ALTS). Cancer 2005 Oct 25;105(5):253-62.
  56. The ASCUS-LSIL Triage Study (ALTS) Group (Edwards RP). The distribution of neoplasia arising on the cervix: results from the ALTS Trial. Am J Obstet Gynecol. 2005 Oct;193(4):1331-7.
  57. The ASCUS-LSIL Triage Study (ALTS) Group (Edwards RP). A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears. Am J Clin Pathol. 2005 Nov;124(5):722-32.
  58. Peters DG, Kudla DM, DeLoia JA, Chu TJ, Fairfull L, Edwards RP, Ferrell RE. Comparative gene expression analysis of ovarian carcinoma and normal ovarian epithelium by serial analysis of gene expression. Cancer Epidemiology, Biomarkers & Prevention, 2005 Jul;14(7):1717-23.
  59. Heron DE, Axtell A, Gerszten K, Amortegui A, Kelly J, Comerci J, Edwards RP. Villoglandular adenocarcinoma of the cervix recurrent in an episiotomy scar: A case report in a 32 year old female. International Journal of Gynecologic Cancer 2005;15:366-371.
  60. Gordon AN, Finkler N, Edwards RP, Garcia AA. Crozier M, Irwin DH, Barrett E.  Efficacy and safety of erlotinib HC1, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 15:785-792, 2005.
  61. Beriwal S, Jain S, Heron D, Kim H, Gerszten K, Edwards RP, Kelley JL. Clinical outcome with adjuvant treatment of endometrial carcinoma using intensity-modulated radiation therapy. Gynecol Oncol. 2006 Aug;102(2):195-9. Epub 2006 May 2.
  62. Beriwal S, Heron DE, Kim H, King G, Shogan J, Bahri S, Gerszten K, Lee J, Kelley JL, Edwards RP.  Intensity-Modulated Radiotherapy for the Treatment of Vulvar Carcinoma. A Comparative Dosimetric Study with Early Clinical Outcome. Int J Radiation Oncology Biol Phys, Nov 2005; 64: 1395-1400.
  63. The ASCUS-LSIL Triage Study (ALTS) Group (Edwards RP). Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst. 2006 Jan 18;98(2):92-100.
  64. The ASCUS-LSIL Triage Study (ALTS) Group (Edwards RP). Number of Cervical Biopsies and Sensitivity of Colposcopy. Obstet Gynecol 2006 Aug;108:264-72.
  65. Beriwal S, Heron D, Rawlins C, Gan GN, Edwards RP, Kelley JL. Early clinical outcome with concurrent chemotherapy with extended-field radiotherapy using IMRT for cervical cancer. Int J Rad Onc Biol Phys, 2007 May 1;68(1);166-71. Epub 2007 Feb 22.
  66. Beriwal S, Bhatnagar A, Heron DE, Selvaraj R, Mogus R, Kim H, Gerszten K, Kelley J, Edwards RP. High dose rate interstitial brachytherapy for gynecologic malignancies. Brachytherapy 2006 Oct-Dec;5(4):218-22.
  67. The ASCUS-LSIL Triage Study (ALTS) Group (Edwards RP). Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis. 2006 Nov 1;194(9), Epub 2006 Sept 27.
  68. The ASCUS-LSIL Triage Study (ALTS) Group (Edwards RP). Predicting absolute risk of CIN 3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS). Am J Obstet Gynecol. 2006 Aug;195(2):341-8.
  69. The ASCUS-LSIL Triage Study (ALTS) Group (Edwards RP). Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol. 2006 Aug;108(2):264-72.
  70. The ASCUS-LSIL Triage Study (ALTS) Group (Edwards RP). Description of patients with squamous cell carcinoma in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study. Cancer. 2006 Aug 25;108(4):212-21.
  71. Helm CW, Toler CR, Martin RS 3rd, Gordinier ME, Parker LP, Metzinger DS, Edwards RP. Cytoreduction and intraperitoneal heated chemotherapy for the treatment of endometrial carcinoma recurrent within the peritoneal cavity. Int J Gynecol Cancer, 2007 Jan-Feb;17(1):204-9.
  72. Gayther SA, Song H, Ramus SJ, Kjaer SK, Whittemore AS, Quaye L, Tyere J, Shadforth D, Hogdall E, Hogdall C, Blaeker J, DiCioccio R, McGuire V, Webb PM, Beesley J, Green AC, Whiteman DC, Goodman MT, Lurie G, Carney ME, Modugno F, Ness RB, Edwards RP, Moysich KB, Goode EL, Couch FJ, Cunningham JM, Sellers TA, Wu AH, Pike MC, Iversen ES, Marks JR, Garcia-Closas M, Brinton L, Lissowska J, Peplonska B, Easton DF, Jacobs I, Ponder B, Schildkraut J, Pearce CL, Chenevix-Trench G, Berchuck A, Paul D.P. Pharoah on behalf of the Ovarian Cancer Association Consortium Tagging Single Nucleotide Polymorphisms in Cell Cycle Control Genes and Susceptibility to Invasive Epithelial Ovarian Cancer. Cancer Research 2007 Apr 1;67(7): 3027-35.
  73. Helm CW, Randall-Whitis L, Martin RS III, Metzinger DS, Gordinier ME, Parker LP, Edwards RP. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol, 2007 Apr;105(1):90-6. Epub 2006 Dec 14.
  74. Beriwal S, Gan GN, Heron DE, Selvaraj RN, Kim H, Lalonde R, Kelley JL, Edwards RP. Early Clinical Outcome with Concurrent Chemotherapy and Extended-Field, Intensity-Modulated Radiotherapy for Cervical Cancer. Int J Radiation Biol Phys. 2007 May 1;68(1):166-71. Epub 2007 Feb 22.
  75. Mantia-Smaldone G, Richard S, Krivak T, Kelley JL, Edwards RP. Pregnancy after tumor debulking and intraperitoneal cisplatin for appendiceal carcinoid tumor. Obstet Gynecol. 2007 Aug; 110(2 Pt 2):477-9.
  76. Wei S, Kryczek I, Edwards RP, Zou L, Szeliga W, Banerjee M, Cost M, Cheng P, Chang A, Redman B, Herberman RB, Zou W. Interleukin-2 Administration Alters the CD4+FOXP3+ T-Cell Pool and Tumor Trafficking in Patients with Ovarian Carcinoma. Cancer Res. 2007 Aug 1; 67(15):7487-94.
  77. Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, Khan SA. Human papillomavirus type 16 reduces the expression of microRNA -218 in cervical carcinoma cells. Oncogene. 2007 Nov 12; (Epub ahead of print).
  78. Lenzi R, Edwards R, June C, Seiden MV, Rosenblum M, Freedman RS. Phase II study of intraperitoneal recombinant interleukin-12 (rhIL012) in patients with peritoneal carcinomatosis (residual disease <1cm) associated with ovarian cancer or primary peritoneal carcinoma. Journal of Translational Medicine 2007, 5:66.
  79. Richard SD, Krivak TC, Castleberry A, Beriwal S, Kelley JL, Edwards RP, Sukumvanich P. Survival for Stage IB Cervical Cancer with Positive Lymph Node Involvement: A Comparison of Completed vs. Abandoned Radical Hysterectomy. PMID: 182344297 (PubMed – indexed for MEDLINE) Gynecol Oncol. 2008 Apr;109(1):43-8.Epub 2008 Jan 29.
  80. Pearce CL, Wu AH, Gayther SA, Bale AE, Beck PA, Beesley J, Chanock S, Cramer DW, DiCioccio R, Edwards, RP, Fredericksen ZS, Garcia-Closas M, Goode EL, Green AC, Hartmann LC, Hogdall E, Kjaer SK, Lissowska J, McGuire V, Modugno F, Moysich K, Ness RB, Ramus SJ, Risch HA, Sellers TA, Song H, Stram DO, Terry KL, Webb, PM, Whitman, DC, Whittemore, AS, Zheng W, Pharoah PDP, Chenevix-Trench G, Pike MC, Schildkraut J, Berchuck A. Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium Pooled Analysis. British Journal of Cancer, (2008 Jan.) 98:282.
  81. Coon D, Beriwal S, Heron DE, Kelley JL, Edwards RP, Sukumvanich P, Zorn KK, Krivak TC. High Dose Rate Rotte “Y” Applicator Brachytherapy for Definitive Treatment of Medically Inoperable Endometrial Cancer: 10-Year Results. PMID: 18258388 (PubMed – indexed for MEDLINE) Int J Radiat Oncol Biol Phys. 2008Jul 1;71(3):779-83. Epub 2008 Feb. 6.
  82. Beriwal S, Heron DE, Mogus R, Edwards RP, Kelley JL, Sukumvanich P. High-dose rate brachytherapy (HDRB) for primary or recurrent cancer in the vagina. PMID 18271948 (Pub Med – indexed for MEDLINE) PMCID:2270281 Radiat Oncol. 2008 Feb 13;3(1):7.
  83. Gusani NJ, Cho SW, Colovos C, Seo S, Franko J, Richard SD, Edwards RP, Brown CK, Holzman MP, Zeh HJ, Bartlett DL. Aggressive surgical management of peritoneal carcinomatosis mortality in a high-volume tertiary cancer center. Ann Surg Oncol. 2008 Mar;15(3):754-63. Epub 2007 Dec. 12.
  84. Beriwal S, Coon D, Heron DE, Kelley, JL, Edwards RP, Sukumvanich P, Zorn KK, Krivak TC. Preoperative intensity-modulated radiotherapy and chemotherapy for locally advanced vulvar carcinoma.(PMID:18455637 (PubMed – indexed for MEDLINE) Gynecol Oncol. 2008 May;109(2):291-5.
  85. Latimer JJ, Johnson JM, Miles TD, Dimsdale JM, Edwards RP, Kelley JL, Grant SG. Cell-type-specific level of DNA nucleotide excision repair in primary human mammary and ovarian epithelial cell cultures. (PMID: 18575893 (PubMed – indexed for MEDLINE). Cell and Tissue Research 2008 Sep;333(3):461-7. Epub 2008 June 25.
  86. Linkov F, Edwards R, Balk J, Yurkovetsky Z, Stadterman B, Lokshin A, Taioli E. Endometrial hyperplasia, endometrial cancer and prevention: Gaps in existing research of modifiable risk factors. European Journal of Cancer, Vol. 44, (2008)12, Pages 1632-1644.
  87. Fader AN, Edwards RP, Cost M, Kanbour-ShakirA, Kelley JL, Schwartz B, Sukumvanich P, Comerci J, Sumkin J, Elishaev E, Rohan L. Sentinel Lymph Node Biopsy in Early-Stage Cervical Cancer: Utility of Intraoperatvie Versus Postoperative Assessment. (PMID: 18684499(PubMed – indexed for MEDLINE) Gynecol Oncol.2008 Oct; 11191):13-7. Epub 2008 Aug 5.
  88. Coon, D, Beriwal, S, Heron, D, Kelley, J, Edwards, R, Sukumvanich, P, Zorn, K, Krivak, T. High-Dose-Rate Rotte “Y” Applicator Brachytherapy for Definitive Treatment of Medically Inoperable Endometrial Cancer: 10-Year Results.PMID 18258388 (PubMed – indexed for MEDLINE) Int. J. Radiation Oncology Biol Phys. 2008 Jul 1; 71(3):779-83. Epub 2008 Feb. 6.
  89. Ragin, C, Edwards, R, Heron, D, Kuo, J, Wentzel, E, Gollin, S. Taioli, E. Prevalence of Cancer-Associated Viral Infections in Healthy Afro-Caribbean Populations: A Review of the Literature. Cancer Investigation, 26:936-947, 2008.
  90. Pearce, CL, WU, AH, Gayther, SA, Bale, AE, Australian Cancer Study (Ovarian Cancer) and Australian Ovarian Cancer Study Group, Beck, PA, Beesley, J, Chanock, S, Cramer, DW, DiCioccio, R, Edwards, R., Fredericksen, ZS, Garcia-Closas, M, Goode EL, Green, AC, Hartmann, LC, Hogdall, E, Kjaer, SK, Lissowskra, J, McGuire, V, Modugno, F, Moysich, K, Ness, RB, Ramus, SJ, Risch, HA, Sellers, TA, Song, H, Stram, DO, Terry, KL, Webb, PM, Whiteman, DC, Whittemore, AS, Zheng, W, Pharoah, PDP, Chenevix-Trench, G, Pike, MC, Schildkraut, J, Berchuck, A on behalf of the Ovarian Cancer Association Consortium (OCAC). British Journal of Cancer (2008) 98, 282-288
  91. Vlad A.M., Kettel, J.D., Edwards, R.P., Finn, O.J.  Mucin 1 (MUC1) Glycoprotein Modulates the Ability of Activated T Cells to Adhere to Endothelia Through Increased Binding to ICAM-1 and Decreased Adhesion to E-Selectin.  Journal of Cellular & Molecular Medicine (2009).
  92. Ramus SJ, Vierkant RA, Johnatty SE, Pike MC, Van Den Berg DJ, Wu AH, Pearce CL, Menon U, Gentry-Maharaj A, Gayther SA, Dicioccio RA, McGuire V, Whittemore AS, Song H, Easton DF, Pharoah PD, Garcia-Closas M, Chanock S, Lissowska J, Brinton L, Terry KL, Cramer DW, Tworoger SS, Hankinson SE, Berchuck A, Moorman PG, Schildkraut JM, Cunningham JM, Liebow M, Kjaer SK, Hogdall E, Hogdall C, Blaakaer J, Ness RB, Moysich KB, Edwards RP, Carney ME, Lurie G, Goodman MT, Wang-Gohrke S, Kropp S, Chang-Claude J; Australian Ovarian Cancer Study Group; Australian Cancer Study (Ovarian Cancer), Webb PM, Chen X, Beesley J, Chenevix-Trench G, Goode EL; Ovarian Cancer Association Consortium. Consortium analysis of 7 candidate SNPs for ovarian cancer. (PMID: 18431743 (PubMed – indexed for MEDLINE) PMCID: PMC2667795.  Int J Cancer. 2008 Jul 15;123(2):380-8.
  93. Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, Khan SA. Human papillomavirus Type 16 reduces the expression of micro RNA-218 in cervical carcinoma cells. Oncogene, (2008) 27:2575.
  94. Finn, OJ, Edwards RP, Human Papillomavirus Vaccine for Cane Prevention. (PubMed – indexed for MEDLINE) N Engl J. Med 2009Nov 5;361(19):1899-90. PMID: 198901134
  95. Naumann RW, Edwards RP, Sukumvanich P. Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer. (PMID 19410281 (PubMed – indexed for MedLINE) Gynecol. Oncol. 2009 Jul:114(1):37-41. Epub 2009 Aug. 12. PMID: 19410281
  96. Pearce CL, Near AM, Van Den Berg DJ, Ramus SJ, Gentry-Maharaj A, Menon U, Gayther SA, Anderson, AR, Edlund CK, Wu AH, Chen, X, Beesley J, Webb PM, Holt SK, Chen C, Doherty JA, Rossing MA, Whittemore AS, McGuire V, DiCioccio RA, Goodman MT, Lurie G, Carney ME, Wilkens LR, Ness RB, Moysich KB, Edwards R. Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. British Journal of Cancer, (2009 Jan) 100:412-420.
  97. Braly P, Nicodemus CF, Chu C, Collins Y, Edwards R, Gordon A, McGuire W, Schoonmaker C, Whiteside T, Smith M, Method M. The Immune Adjuvant Properties of Front-Line Carboplatin-Paclitaxel: A Randomised Phase II Study of Alternative Schedules of Intravenous Oregovomab-Chemo-Immunotherapy in Advanced Ovarian Cancer. Journal of Immunotherapy, 2009;32(1):54-65.
  98. Ragin CC, Watt A, Markovic N, Bunker CH, Edwards RP, Eckstein S, Fletcher H, Garwood D, Collin SM, Jackson M, Patrick AL, Smikle M, Taioli E, Wheeler VW, Wilson JB, Younger N, McFarlane-Anderson N. Comparisons of high-risk cervical HPV infections in Caribbean and US populations. (PMID 19208214) Infect Agent Cancer. 2009 Feb. 10; 4 Suppl 1:S9.
  99. Ragin CC, Edwards RP, Jones J, Thurman NE, Hagan KL, Jones EA, Moss CM, Smith AC, Akers A, Gollin SM, Heron DE, Andraos-Selim C, Bondzi C, Robertson L, Taioli E. Knowledge about human papillomavirus and the HPV vaccine – a survey of the general population. (PMID 19208201 (PubMed – in process) Infect. Agent Cancer. 2009 Feb. 10;4 Suppl 1:S10.
  100. Zamboni WC, Ramalingam S, Friedland DM, Edwards RP, Stoller RG, Strychor S, Maruca L, Zamboni BA, Belani CP, Ramanathan RK. Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. PMID 19190127 (Pub-Med – indexed for MEDLINE) Clin Cancer Res. 2009 Feb. 15; 15(4):1466-72.Epub 2009 Feb 3. Erratum in: Clin Cancer Res. 2009 Apr 15; 15(8):2949-50. PMID: 19190127
  101. Budiu, RA, Diaconu J, Chrissluis R, Dricu A, Edwards, RP, Vlad AM. A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-MUC1 antibodies and Foxp3+regulatory T. cells. Disease Models & Mechanisms 2, 593-603 (2009) Published by The Company of Biologists 2009. PMID: 19190127
  102. Zamboni WC, Strychor S, Maruca L, Ramalingam S, Zamboni BA, WU H, Friedland DM, Edwards RP, Stoller RG, Belani CP, and Ramanathan RK. Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies, Clinical Pharmacology & Therapeutics, Vol 86, No 5, November 2009 (10:1038/clpt.2009.151). PMID: 19675541.
  103. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G, on behalf of the HPV-010 Study Group. Comparison of the immunogenicity and safety of CervarixTM and GardasilR human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. (PMID: 19684472 (PubMed – in process) Hum Vaccin. 2009 Oct;5(10:705-19. Epub 2009 Oct 14.
  104. Lesnock JL, Richard SD, Zorn KK, Krivak TC, Beriwal S, Sukumvanich P, McBee, Jr. WC, Kelley JL, Edwards, RP. Completion of Intraperitoneal Chemotherapy in Advanced Ovarian Cancer and Catheter-Related Complications. Gynecol Oncol 116:345-50, 2010. PMID: 19959211
  105. Helm CW, BChir, Richard SD, Pan J, Bartlett D, Goodman MD, Hoefer R, Lentz SS, Levine EA, Loggie BW, Metzinger DS, Miller B, Parker L, Spellman JE, Sugarbaker PH, Edwards RP, Rai SN.  Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer – First Report of the HYPER-O Registry. PMID 20130504 (PubMed – in process) International Journal of Gynecological Cancer, Volume 20, Number 1, 2010 Jan; 20(1):61-9. PMID: 20130504 (PubMed – indexed for MEDLINE).
  106. Wegner RE, Beriwal S, Heron DE, Richard SD, Kelley JL, Edwards RP, Sukumvanich P, Zorn KK, Krivak TC. Definitive radiation therapy for endometrial cancer in medically inoperable elderly patients. Brachytherapy 2010 Jan 30 (Epub). PMID: 20122872.
  107. Vlad AM, Budiu RA, Lenzner DE, Wang Y, Thaller JA, Colonello K, Crowley-Nowick PA, Kelley JL, Price FV, Edwards RP. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother, 59, 293-301 (2010) (Cited in Nature Cancer Reviews March 2010) PMID: 19690755.
  108. Phelan CM, Tsai Y, Goode EL, Cunningham JM, Vierkant RA, Fridley BL, Australian Cancer Study (Ovarian Cancer), Beesley J, Chen X, Webb PM, Australian Ovarian Cancer Study Group, Chanock S, Cramer DW, Moysich K, Edwards RP, Chang-Claude J, Garcia-Closas M, Yang H, Wang-Gohrke S, Kropp S, Green AC, Lissowska J, Carney ME, Lurie G, Wilkens LR, Modugno F, Ness RB, Pearce CL, Wu AH, Van Den Beg DJ, Stram DO, Terry KL, Whiteman DC, Whittemore A, DiCioccio RA, McGuire V, Doherty JA, Rossing MA, Anton-Culver H, Ziogas A, Hogdall C, Hogdall E, Kjaer SK, Blaakaer J, Quaye L, Ramus SJ, Jacobs I, Pharoah P, Iversen ES, Marks JR, Pike MC, Gayther SA, Goodman MT, Schildkraut JM, Chenevix-Trench G, Berchuck A, Sellers TA on behalf of the Ovarian Cancer Association Consortium (OCAC).  Polymorphism in the GALNT1 Gene and Epithelial Ovarian Cancer in Non-HGispanic White Women: the Ovarian Cancer Association Consortium. PMID: 20142253 (PubMed – in process). Cancer Epidemiol Biomarkers & Prevention 2010 Feb; 19(2):600-4. PMCID: PMC2880167. PMID: 20142253.
  109. Posluszny, D.M., Edwards, R.P., Dew, M.A. & Baum, A. Perceived threat and PTSD symptoms in women undergoing surgery for gynecologic cancer or benign conditions. Psycho-Oncology 20:783-787 2011.  (PMID: 20878863).
  110. Felix AS, Edwards R, Bowser R, Linkov F. Chemokines and cancer progression: A qualitative review on the role of stromal cell-derived factor 1-alpha and CXCR4 in endometrial cancer. Cancer Microenvironment. 2010;Vol:pages.
  111. Felix A, Weissfeld JL, Edwards R, Linkov F. Future Directions in the Field of Endometrial Cancer Research: The Need to Investigate the Tumor Microenvironment. European Journal of Gynecologic Oncology. 2010;31(2):139-144
  112. Vergote I, Finkler JN, Hall JB, Melnyk O, Edwards RP, Jones M, Keck JG, Meng L, Brown GL, Rankin EM, Burke JJ, Boccia V, Runowicz CD, Rose PG. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2010 Jul;20(5):772-80 (PMID 20973267 (PubMed – indexed for MEDLINE).
  113. Richard, SD, Sukumvanich P, Lesnock JL, McBee WC, Beriwal S, Edwards, RP, Zorn KK, Krivak T. Intraperitoneal Catheter Leads to Prolongation fo the Time to Normalization of Serum CA125 Levels. Int J. Gynecol Cancer.  2010 Aug;20(6):932-5. PMID 20683398 (PubMed – indexed for MEDLINE).
  114. Smaldone GM, Richard SD, Edwards RP. Pregnancy outcomes after conservative surgical management of ovarian neoplasms treated at a single institution. Int J Gynecol Cancer. 2010 Aug;20(6):926-5. PMID: 20683398 (PubMed – indexed for MEDLINE).
  115. Teng PN, Rungruang BJ, Hood BL, Sun M, Flint MS, Bateman NW, Dhir R, Bhargava R, Richard SD, Edwards RP, Conrads TP. Assessment of buffer systems for harvesting proteins from tissue interstitial fluid for proteomic analysis. J. Proteome Res. 2010 Aug 6;9(8)4161-9 PMID: 20518575 (PubMed – indexed for MEDLINE).
  116. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhass J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brook-Wilson A, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinenen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Durst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X; Australian Ovarian Cancer Study Group; Austrialian Cancer Study (Ovarian Cancer); Ovarian Cancer Association Consortium, Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trency G, Pharoah PD, Gayther SA. Common variants at 19p 13 are associated with susceptibility to ovarian cancer. Nat Genet. 2010 Oct; 42(10):880-4. Epub 2010 Sep 19. PMID: 20852633 (PubMed – indexed for MEDLINE).
  117. Felix AS, Weissfeld J, Stone R, Bowser R, Chivukula M, Edwards R, Linkov F. Factors associated with Type I and Type II endometrial cancer. Cancer Causes and Control. 2010 Nov;21(11): 1851-6. Epub 2010 Jul 14. PMID: 20628804 (PubMed – indexed for MEDLINE).
  118. Mantia-Smaldone, GM, Edwards, RP, Vlad, AM. Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies. Cancer Management and Research 2011:3 25-38. (PMID: 21734812 (PubMed).
  119. Monk BJ, Sill MW, Hanjani P, Edwards R., Rotmensch J, DeGeest K, Bonebrake AJ, Walker JL. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of Gynecologic Oncology Group. PMID:21144560. Gynecol Oncol. 2011 Mar;120(3):459-63. Epub 2010 Dec 7.
  120. Zamboni WC, Combest AJ, Deloia JA, Edwards RP, Bridges AS, Zamboni BA, Walko CM, Yu AY, Krivak TC, Kelley JL. Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer. Cancer Chemother Pharmacol. 2011 Mar 25. PMID: 21437702
  121. Chivukula, M, Niemeier, L, Edwards, R, Nikiforova, M, Mantha, G, McManus, K, Carter, Gl. Carcinomas of distal fallopian tube and their association with tubal intraepithelial carcinoma: Do they share a common “precursor” lesion? Loss of heterozygosity and immunohistochemical Analysis using PAX 2, WT-1, and P53 Markers. ISRN Obstetrics and Gynecology, Volume 2011, Article ID 858647 (PMID: 21826275)
  122. William C. McBee, Amy S. Gardiner, Robert P. Edwards, Jamie L. Lesnock, Rohit Bhargava, R. Marshall Austin, Richard S. Guido and Saleem A. Khan. MicroRNA Analysis in Human Papillomavirus (HPV)-Associated Cervical Neoplasia and Cancer. Journal of Carcinogene Mutagene, Volume 2, Issue 1, 1000114, 2011, ISSN:2157-2518.
  123. Ness RB, Dodge RC, Edwards RP, Baker JA, Moysich KB. Contraception Methods, Beyond Oral Contraceptives and Tubal Ligation and Risk of Ovarian Cancer. Ann Epidemiol 2011 Mar;21(3): 188-96.  PMID: 21109450 (PubMed – indexed for MEDLINE).
  124. Richard SD, Bencherif B, Edwards RP, Elishaev E, Krivak TC, Mountz JM, Deloia, JA. Noninvasive assessment of cell proliferation in ovarian cancer using (18F) 3’deoxy-3-fluorothymidine positron emission tomography/computer tomography imaging. Nucl Med Biol. 2-11 May; 38(4):485-91.Epub 2011 Mar 3 (PMID: 21531285).
  125. Taylor SE, McBee WC, Richard SD, Edwards RP. Radical hysterectomy for early stage cervical cancer: laparoscopy versus laparotomy. JSLS. 2011 Apr-Jun;15(2):213-7. PMID: 21902978
  126. Padilla-Raygoza N, Laporte R, Shubnikov E, Hennon M, Edwards RP, Linkov F. Cancer and Chronic Diseases in Minority Populations: The Need for More Educational Materials in Spanish for Healthcare Providers. J Immig Minor Health. 2011 May 11. (PMID: 21559967).
  127. Ragin C, Edwards R, Larkins-Pettigrew M, Taioli, Eckstein S, Thurman N, Bloome J, Markovic N. Oral HPV Infection and Sexuality: A Cross-Sectional Study in Women. Int. J. Mol. Sci. June 2011, 12, 3928-3940; doi:10.3390/ijms12063928 (ISSN1422-0067).
  128. Beriwal S, Rwigema JC, Higgins E, Kim H, Houser C, Sukumvanich P, Olawaiye A, Richard S, Kelley JL, Edwards RP, Krivak TC. 3D image-based HDR interstitial brachytherapy for vaginal cancer. Brachytherapy 2011 Jun 10. PMID: 21665553
  129. Zamboni WC, Maruca LJ, Strychor S, Zamboni BA, Ramalingam S, Edwards RP, Kim J, Bang Y, Lee H, Friedland DM, Stoller RG, Belani CP, Ramanathan RK. Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors. J Liposome Res. 2011 Jun;21(2): 158-65. Doi: 10.3109/08982104.2010.496085. Epub 2010 Jul 14. PMID: 20626314
  130. Felix AS, Stone RA, Bowser R, Chivukula M, Edwards RP, Weissfeld JL, Linkov F. Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-rate endometrioid, clear cell, and papillary serous endometrial cancers. Int. Journal Gynecol Cancer. 2011 Jul;21(5):877-84. PMID: 21666484.
  131. Budiu RA, Mantia-Smaldone G. Elishaev E, Chu T, Thalle J McCabe K, Lenzner D, Edwards RP, Vlad AM. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunol Immunother. 2011 Jul;60(7):975-84. Epub 2011 Apr 2. PMID: 21461842
  132. Edwards, Robert P. Is hyperthermic intraoperative peritoneal chemotherapy and systemic chemotherapy as effective as standard intraperitoneal chemotherapy: time for a prospective trial? Lead Editorial on HIPEC: Gynecologic Oncology 2011 Aug 122(2):207-208 (PMID: 21763889 (PubMed – in process).
  133. Posluszny DM, Baum A, Edwards RP, Dew MA. Posttraumatic growth in women one year after diagnosis for gynecologic cancer or benign conditions. J Psychosoc Oncol. 2011 Sep-Oct;29(5):561-72. PMID: 21882935
  134. Felix AS, Store RA, Chivukula M, Bowser R, Parwani AV, Linkov F, Edwards RP, Weissfeld JL. Survival outcomes in endometrial cancer patients are associated with CXCL 12 and estrogen receptor expression. International Journal of Cancer. 2011 Oct 25 (PMID: 22025313).
  135. Natasa Obermajer, Ravikumar Muthuswamy, Jamie Lesnock, Robert P. Edwards, Pawel Kalinski. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood, 17 November 2011, Volume 118. Number 20 (5498-5505. PMID: 21972293
  136. Hoskins ER, Hood BL, Sun M, Krivak TC, Edwards RP, Conrads TP. Proteomic analysis of ovarian cancer proximal fluids: validation of elevated peroxiredoxin 1 in patient peripheral circulation. PLoS One. 2011;6(9):325056. (PMID: 21980378)
  137. Obermajer N., Muthuswamy, R., Odunsi K, Edwards RP, Kalinski P. PGE2-Induced CXCL 12 Production and CXCR4 Expression Controls the Accumulation of Human MDSCs in Ovarian Cancer Environment. Cancer Research. 2011 Dec. 15;71(24):7463-70. PMID: 22025564
  138. Lo-Ciganic WH, Zgibor JC, Bunker CH, Moysich KB, Edwards RP, Ness RB. Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drugs, or Acetaminophen and Risk of Ovarian Cancer. Epidemiology. 2012 Jan 16. (Epub ahead of print). (PMID: 22252409).
  139. Skaznik-Wikiel ME, Lesnock JL, McBee WC, Beriwal S, Zorn KK, Richard SD, Krivak TC, Edwards RP. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes. Int J. Gynecol Cancer 2012 Feb;22(2):232-7. PMID: 22080886
  140. Malgorzata E Skaznik-Wikiel, Paniti Sukumvanich, R. Marshall Austin, Kristin K. Zorn, Thomas C. Krivak, Robert P. Edwards, Alexander B. Olawaiye. Heavy Cervical Cancer Burden in Elderly Women: How Can We Improve the Situation. Gynecologic Cytopathology 2012;56:388-393. April 2, 2012. PMID: 22846717.
  141. Feng Qian, Jianqun Liao, Jeannine Villella, Robert Edwards, Pawel Kalinski, Shashikrant Lele, Protul Shrikant, Kunle Odunsi. Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation. Cancer Immunol Immunother. 2012 Nov;61(11):2013-20. doi: 10.1007/s00262-012-1265-x. Epub 2012 Apr 22. (PMID: 22527253).
  142. Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, Godoy H, Lele S, duPont N, Edwards R, Shrikant P, Old LJ, Gnjatic S, Jäger E. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5797-802. doi: 10.1073/pnas.1117208109. Epub 2012 Mar 27. PMID:22454499. [PubMed - indexed for MEDLINE].
  143. T. Clark Gamblin, MD, H. Richard Alexander, MD, Robert Edwards, MD, and David L. Bartlett, MD. Concepts of Regional Therapies for Advanced Malignancy. Ann Sur Oncol . May 2012. Vol 19, Issue 5, pp 1371-1372.
  144. Felix AS, Edwards RP, Stone RA, Chivukula M, Parwani AV, Bowser R, Linkov F, Weissfeld JL. Associations between hepatocyte growth factor, c-Met, and basic fibroblast growth factor and survival in endometrial cancer patients. Br J Cancer. 2012. British Journal of Cancer 2012 Jun 5;106(12):2004-9. doi: 10.1038/bjc.2012.200. Epub 2012 May 22. PMID: 2267129
  145. RA Budiu, E Elishaev, J Brozick, M Lee, RP Edwards, P Kalinski, AM Vlad. Immunobiology of human mucin 1 in a preclinical ovarian tumor model. Oncogene (2012), 1-12. July 2012. PMID: 22964632
  146. Huali Wu, Ramesh Ramanathan, Beth A Zamboni, Sandra Strychor, Suresh Ramalingam, Robert P. Edwards, David M. Friedland, Ronald G. Stoller, Chandra P Belani, Lauren J Maruca, Yung-Jue Bang, William C Zamboni. Mechanism-based model characterizing bidirectional inter action between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients. International Journal of Nanomedicine 2012:7 555-5564.
  147. Francesmary Modugno, PHD, MPH and Robert P. Edwards, MD. Ovarian Cancer: Prevention, Detection and Treatment of the Disease and its Recurrence. Molecular Mechanisms and Personalized Medicine Meeting Report. Int J Gynecol Cancer 2012, 22: S45-S47. July 26, 2012. PMID: 23013733
  148. Wu, H, Ramanathan, RK, Zamboni, BA, Strychor, S, Ramalingam, S, Edwards, R, Friedland, DM, Stoller, RG, Belani, CP, Maruca, LJ, Bang, Y, Zamboni, WC. Mechanism-based model characterizing bidirectional ineraction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients. International Journal of Nanomedicine 2012:7 5555-5564. PMID: 23112576 (PubMed-indexed for MEDLINE)
  149. Michelle Kurta, Kristen Moysich, Joel Weissfeld, Ada Youk, Clareann H. Bunker, Robert P. Edwards, Francesmary Modugno, Roberta Ness, and Brenda Diergaarde. Use of Fertility Drugs and Risk of Ovarian Cancer: Results from a U.S.-Based Case-Conrol Study. Cancer Epidemiol Biomarkers Prev; 21(8) August 2012. PMID: 22707710
  150. Sushil Beriwal, Neeta Kannan, Paniti Sukumvanich, Scott D. Richard, Joseph L. Kelley, Robert P. Edwards, Alexander Olawaiye, Thomas C. Krivak. Complete metabolic response after definitive radiation therapy for cervical cancer: Patterns and factors predicting for recurrence.  Accepted 7 August 2012, Gynecologic Oncology 127 (2012) 303-3006. PMID: 22902917
  151. Collaborative Group on Epidemiological Studies of Ovarian Cancer (Edwards RP and Modugno FM). Ovarian cancer and smoking: individual participant meta-analysis including 114 women with ovarian cancer from 51 epidemiological studies. Lancet Oncol. 2012 September; 13(9): 936-945. PMID: 22863523
  152. Neeta Kannan, Sushil Beriwal, Hayeon Kim, Christopher Houser, Robert Mogus, Paniti Sukumvanich, Alexander B. Olawaiye, Scott Richard, Joseph L. Kelley, Robert Edwards, Thomas C Krivak. High-dose-rate interstitial computed tomography-based brachytherapy for the treatment of cervical cancer: Early results. Brachytherapy Volume 11, Issue 5, September-October 2012, pp 408-412. PMID: 22513106
  153. Beriwal S, Shukla G, Shinde A, Heron DE, Kelley JL, Edwards RP, Sukumvanich P, Richards S, Olawaiye AB, Krivak TC. Preoperative intensity modulated radiation therapy and chemotherapy for locally advanced vulvar carcinoma: analysis of pattern of relapse. Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1269-74. doi: 10.1016/j.ijrobp.2012.11.012. Epub 2012 Dec 27. PMID: 23273997
  154. Linda E Kelemen, Elisa Bandera, Kathryn l Terry, Mary Anne Rossing, Louise A. Brinton, Jennifer A Doherty, Roberta B Ness, Susanne Kruger Kjaer, Jenny Chang-Claude, Martin Kobel, Galina Lurie, Pamela J. Thompson, Michael E Carney, Kirsten Moysich, Robert Edwards, Clare Bunker, Allan Jensen, Estrid Hogdall, Daniel W. Cramer, Allison F. Vitonis, Sara H Olson, Melony King, rmila Chandran, Jolanta Lissowska, Montserrat Garcia-Closas, Hannah Yang, Penelope M Webb, Joellen M Schildkraut, Mac T. Goodman, Harvey A. Risch, on behalf of the Australian ovarian Cancer Study Group and Australian Cancer Study (Ovarian Cancer) and on behalf of the Ovarian Cancer Association Consortium. Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of ,342 cases and 10,358 controls from the Ovarian Cancer Association consortium. BMC Cancer 2013, 13:28.
  155. Suryawanshi S, Vlad AM, Lin HM, Mantia-Smaldone G, Laskey R, Lee M, Lin Y, Donnellan N, Klein-Patel M, Lee T, Mansuria S, Elishaev E, Budiu R, Edwards RP, Huang X. Plasma MicroRNAs as Novel Biomarkers for Endometriosis and Endometriosis-Associated Ovarian Cancer. Clin Cancer Res. 2013 Mar 1;19(5):1213-1224. Epub 2013 Jan 29. PMID:23362326.
  156. Mette T. Faber, Susanne K. Kjær, Christian Dehlendorff, Jenny Chang-Claude,Klaus K. Andersen, Estrid Høgdall, Penelope M. Webb, Susan J. Jordan,The Australian Cancer Study (Ovarian Cancer), Australian Ovarian Cancer Study Group, Mary Anne Rossing, Jennifer A. Doherty, Galina Lurie, Pamela J. Thompson, Michael E. Carney, Marc T. Goodman, Roberta B. Ness, Francesmary Modugno, Robert P. Edwards, Clareann H. Bunker, Ellen L. Goode, Brooke L. Fridley, Robert A. Vierkant, Melissa C. Larson, Joell15en Schildkraut, Daniel W. Cramer, Kathryn L. Terry, Allison F. Vitonis, Elisa V. Bandera, Sara H. Olson, Melony King, Urmila Chandran, Lambertus A. Kiemeney, Leon F. A. G. Massuger, Anne M. van Altena, Sita H. Vermeulen, Louise Brinton, Nicolas Wentzensen,,Jolanta Lissowska, Hannah P. Yang, Kirsten B. Moysich, Kunle Odunsi, Karin Kasza, Oluwatosin Odunsi-Akanji, Honglin Song, Paul Pharaoh, Mitul Shah, Alice S. Whittemore, Valerie McGuire, Weiva Sieh, Rebecca Sutphen, Usha Menon, Simon A. Gayther, Susan J. Ramus, Aleksandra Gentry-Maharaj, Celeste Leigh Pearce, Anna H. Wu, Malcolm C. Pike, Harvey A. Risch, Allan Jensen, On behalf of the Ovarian Cancer Association Consortium. Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. Cancer Causes Control. 2013 Mar 2. (Epub ahead of Print) PMID:23456270.
  157. Beriwal S, Shukla G, Shinde A, Heron DE, Kelley JL, Edwards RP, Sukumvanich P, Richards S, Olawaiye AB, Krivak TC. Preoperative intensity modulated radiation therapy and chemotherapy for locally advanced vulvar carcinoma: analysis of pattern of relapse. Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1269-74. PMID: 23273997
  158. Paul DP Pharoah1,2,107, Ya-Yu Tsai3,107, Susan J Ramus4,107, Catherine MPhelan3,107, Ellen LGoode5, Kate Lawrenson4, Melissa Buckley3, Brooke LFridley5, Jonathan P Tyrer1, Howard Shen4, Rachel Weber6, Rod Karevan4, Melissa CLarson7, Honglin Song1, Daniel CTessier8,9, François Bacot8,9, Daniel Vincent8,9, Julie MCunningham10, Joe Dennis2, Ed Dicks1, Australian Cancer Study11 , Australian Ovarian Cancer Study Group11, Katja KAben12,13, Hoda Anton-Culver14, Natalia Antonenkova15, Sebastian MArmasu7, Laura Baglietto16,17, Elisa V Bandera18, Matthias WBeckmann19, Michael J Birrer20,21, Greg Bloom3, Natalia Bogdanova22, James DBrenton23, Louise A Brinton24, Angela Brooks-Wilson25, Robert Brown26, Ralf Butzow27,28, Ian Campbell29,30, Michael ECarney31, Renato SCarvalho3, Jenny Chang-Claude32, Y Anne Chen3, Zhihua Chen3, Wong-Ho Chow33, Mine SCicek5, Gerhard Coetzee34, Linda SCook35, Daniel WCramer36,37, Cezary Cybulski38, Agnieszka Dansonka-Mieszkowska39, Evelyn Despierre40, Jennifer A Doherty41, Thilo Dörk22, Andreas du Bois42,43, Matthias Dürst44, Diana Eccles45, Robert Edwards46,47, Arif B Ekici48, Peter A Fasching19,49, David Fenstermacher3, James Flanagan26, Yu-Tang Gao50, Montserrat Garcia-Closas51,52, Aleksandra Gentry-Maharaj53, Graham Giles16,17,54, Anxhela Gjyshi3, Martin Gore55, Jacek Gronwald38, Qi Guo1, Mari KHalle56,57, Philipp Harter42,43, Alexander Hein19, Florian Heitz42,43, Peter Hillemanns58, Maureen Hoatlin59, Estrid Høgdall60,61, Claus KHøgdall62, Satoyo Hosono63, Anna Jakubowska38, Allan Jensen60, Kimberly R Kalli64, Beth Y Karlan65, Linda EKelemen66,67, Lambertus A Kiemeney12,13,68, Susanne Krüger Kjaer60,62, Gottfried EKonecny49, Camilla Krakstad56,57, Jolanta Kupryjanczyk39, Diether Lambrechts69, Sandrina Lambrechts40, Nhu DLe70, Nathan Lee4, Janet Lee4, Arto Leminen28, Boon Kiong Lim71, Jolanta Lissowska72, Jan Lubiński38, Lene Lundvall62, Galina Lurie31, Leon F A GMassuger73, Keitaro Matsuo63, Valerie McGuire74, John R McLaughlin75,76, Usha Menon53, Francesmary Modugno46,77, Kirsten B Moysich78, Toru Nakanishi79, Steven A Narod80, Roberta B Ness81, Heli Nevanlinna28, Stefan Nickels32, Houtan Noushmehr34,82, Kunle Odunsi78, Sara Olson83, Irene Orlow83, James Paul84, Tanja Pejovic85,86, Liisa MPelttari28, Jenny Permuth-Wey3, Malcolm CPike4,83, Elizabeth MPoole37,87, Xiaotao Qu3, Harvey A Risch88, Lorna Rodriguez-Rodriguez18, Mary Anne Rossing89,90, Anja Rudolph32, Ingo Runnebaum44, Iwona KRzepecka39, Helga B Salvesen56,57, Ira Schwaab91, Gianluca Severi16,17, Hui Shen82, Vijayalakshmi Shridhar10, Xiao-Ou Shu92,93, Weiva Sieh74, Melissa CSouthey94, Paul Spellman95, Kazuo Tajima63, Soo-Hwang Teo96,97, Kathryn LTerry36,37, Pamela J Thompson31, Agnieszka Timorek98,99, Shelley STworoger37,87, Anne Mvan Altena73, David van den Berg4, Ignace Vergote40, Robert A Vierkant5, Allison F Vitonis36, Shan Wang-Gohrke100, Nicolas Wentzensen24, Alice SWhittemore74, Elisabeth Wik56,57, Boris Winterhoff101, Yin Ling Woo71, Anna H Wu4, Hannah P Yang24, Wei Zheng92,93, Argyrios Ziogas14, Famida Zulkifli96,97, Marc TGoodman31, Per Hall102, Douglas F Easton1,2, Celeste LPearce4, Andrew Berchuck103, Georgia Chenevix-Trench104, Edwin Iversen105, Alvaro NA Monteiro3, Simon A Gayther4, Joellen MSchildkraut6,106,108 & Thomas A Sellers3,108.  GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics. Vol. 45/Number 4/April 2013.
  159. Lesnock JL, Arnold RM, Meyn LA, Buss MK, Quimper M, Krivak TC, Edwards RP, Chang JC. Palliative care education in gynecologic oncology: A survey of the fellows. Gynecol Oncol. 2013 May 18. doi:pii: S0090-8258(13)00745-2. 10.1016/j.ygyno.2013.05.012. [Epub ahead of print]
  160. Steffi Oesterreich, Robert Edwards, Anda Vlad. Progestins: Pro-senescence therapy for ovarian cancer? Comment on: Diep CH, et al. Cell Cycle as:11, 1662-2663, June 1, 2013. PMIDD:23574718.
  161. Jeffrey L Wong, Erik Berk, Robert Edwards, and Pawel Kalinski. IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ TCells to the tumor microenvironment. Cancer Res, June 12, 2013. PMID: 23761327
  162. Natasa Obermajer, Jeffrey Wong, Robert P. Edwards, Kong Chen, Melanie Scott, Shabaana Khader, Jay K. Kolls, Kunle Odunsi, Timothy R. Billiar, and Pawel Kalniski. Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling. J Exp. Med. 2013 Jun 24 (Epub ahead of print) Vol. 210 No. 7 1433-1445. PMID: 23797095 (PubMed-in process).
  163. Koebel M, Kalloger S, Lee S, Duggan MA, Kelemen LE, Prentice L, Kalli KR, Fridley FL, Visscher DW, Keeney GA, Vierkant RA, Cunningham JM, Chow C, Ness RB, Moysich KB, Edwards RP, Modugno F, Bunker CH, Wozniak EL, Benjamin E, Gayther SA, Gentry-Maharaj A, Menon U, Gilks B, Huntsman DG, Ramus SJ, Goode EL. Biomarker-based ovarian carcinoma typing: a histological investigation in the Ovarian Tumor Tissue Analysis consortium. Cancer Epidemiol Biomarkers 2013 Oct;22(10):1677-86. doi: 10.1158/1055-9965.EPI-13-0391. Epub 2013 Jul 23. PMID: 23880734
  164. Rutherford T, Orr J Jr, Grendys E Jr, Edwards R, Krivak TC, Holloway R, Moore RG, Puls L, Tillmanns T, Schink JC, Brower SL, Tian C, Herzog TJ. A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. Gynecol Oncol. 2013 Aug 13. pii: S0090-8258(13)01094-9. doi: 10.1016/j.ygyno.2013.08.009. [Epub ahead of print]
  165. Donovan HS, Ward SE, Sereika SM, Knapp JE, Sherwood PR, Bender CM, Edwards RP, Fields M, Ingel R. Web-Based Symptom Management for Women With Recurrent Ovarian Cancer: A Pilot Randomized Controlled Trial of the WRITE Symptoms Intervention. J Pain Symptom Manage. 2013 Sep 6. pii: S0885-3924(13)00318-7. doi: 10.1016/j.jpainsymman.2013.04.005. [Epub ahead of print].
  166. Earp MA, Kelemen LE, Magliocco AM, Swenerton KD, Chenevix-Trench G, Australian Cancer Study, Australian Ovarian Cancer Study Group, Lu Y, Hein A, Ekici AB, Beckmann MW, Fasching PA, Lambrechts D, Despierre E, Vergote I, Lambrechts S, Doherty JA, Rossing MA, Chang-Claude J, Rudolph A, Friel G, Moysich KB, Odunsi K, Sucheston-Campbell L, Lurie G, Goodman MT, Carney ME, Thompson PJ, Runnebaum IB, Dürst M, Hillemanns P, Dörk T, Antonenkova N, Bogdanova N, Leminen A, Nevanlinna H, Pelttari LM, Butzow R, Bunker CH, Modugno F, Edwards RP, Ness RB, du Bois A, Heitz F, Schwaab I, Harter P, Karlan BY, Walsh C, Lester J, Jensen A, Kjær SK, Høgdall CK, Høgdall E, Lundvall L, Sellers TA, Fridley BL, Goode EL, Cunningham JM, Vierkant RA, Giles GG, Baglietto L, Severi G, Southey MC, Liang D, Wu X, Lu K, Hildebrandt MA, Levine DA, Bisogna M, childkraut JM, Iversen ES, Weber RP, Berchuck A, Cramer DW, Terry KL, Poole EM, Tworoger SS, Bandera EV, Chandran U, Orlow I, Olson SH, Wik E, Salvesen HB, Bjorge L, Halle MK, van Altena AM, Aben KK, Kiemeney LA, Massuger LF, Pejovic T, Bean YT, Cybulski C, Gronwald J, Lubinski J, Wentzensen N, Brinton LA, Lissowska J, Garcia-Closas M, Dicks E, Dennis J, Easton DF, Song H, Tyrer JP, Pharoah PD, Eccles D, Campbell IG, Whittemore AS, McGuire V, Sieh W, Rothstein JH, Flanagan JM, Paul J, Brown R, Phelan CM, Risch HA, McLaughlin JR, Narod SA, Ziogas A, Anton-Culver H, Gentry-Maharaj A, Menon U, Gayther SA, Ramus SJ, Wu AH, Pearce CL, Pike MC, Dansonka-Mieszkowska A, Rzepecka IK, Szafron LM, Kupryjanczyk J, Cook LS, Le ND, Brooks-Wilson A, On behalf of the Ovarian Cancer Association Consortium. Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics. Published online: 05 November 2013. DOI 10.1007/s00439-013-1383-3.
  167. John W. Luiza, Sarah E. Taylor, Faye F. Gao, Robert P. Edwards. Placental site trophoblastic tumor: Immunohistrochemistry algorithm key to diagnosis and review of literature. Journal of Gynecologic. 2013 Nov 21;7:13-5. Doi: 10.1016/j.gynor.2013.11.001.eCollection 2014Jan.
  168. Dennis English, MD, MMM, Robert Edwards, MD, Patty Genday, MSN, MBA, RN, Carolyn Maue, MSW, CEAP, and Cynthia Zydel, MBA, BS. Smoothing the Transition from Resident to Attending. Physicians Executive Journal. November 2013.
  169. John Luiza, Sarah Taylor, Faye Gao, Robert Edwards. Placental site trophoblastic tumor: Immunohistochemistry algorithm key to diagnosis and review of literature. Gynecol Oncol Case Rep. Jan 2014; 7: 13-15. Published online Nov 21, 2013. 10.1016/j.gynor.2013.11.001 (PMCID:PMC3895280).
  170. Donovan Heidi, Nolte Susan, Edwards Robert, Wenzel Lari. Nursing research in the gynecologic oncology group. Seminars in Oncology Nursing, Vol 30, No 1 February 2014: pp 44-52.
  171. Linkov F, Burke LE, Komaroff M, Edwards RP, Lokshin A, Styn MA, Tseytlin E, Freese K, Bovbjerg DH An Exploratory investigation of links between changes in adipokines and quality of life in individuals undergoing weight loss interventions: possible implications for cancer research Gynecologic Oncology 2014 Apr;133(1):67-72. doi: 10.1016/j.ygyno.2014.01.019 (Epub ahead of print)
  172. Linkov F, Freese KE, Edwards RP, Bovbjerg DB, Ramanathan R, Gourash W. Stakeholder involvement is essential for patient centered applications of Google Trends research. Surgery for Obesity and Related Diseases. In press. 2014 Mar-Apr;10(2):370-1. doi: 10.1016/j.soard.2013.12.017. PMID: 24679639.
  173. Argenta P, Svendsen C, Elishaev E, Gloyeske N, Geller MA, Edwards, RP, Linkov F. Hormone receptor expression patterns in the endometrium of asymptomatic morbidly obsess women before & after bariatric surgery. Gynecol Oncol. 2014 Apr;133(1):78-82. doi: 10.1016/j.ygyno.2013.12.005. PMID: 24680595 [PubMed - in process].
  174. Qian W, Wang J, Roginskaya V, McDermott LA, Edwards RP, Stolz DB, Llambi F, Green DR, Houten BV. Novel combination of mitochondrial division inhibitor 1 (mdivi-1) and platinum agents produces synergistic pro-apoptotic effect in drug resistant tumor cells. Oncotarget. 2014 May 4.
  175. Tejas S Tirodkar, Raluca A. Budiu, Esther Elishaev, Lixin Zhang, Jyothi T. Mony, Joan Brozick, Robert P. Edwards, Anda M. Vlad. MUC1 Positive, Kras and Pten Driven Mouse Gynecologic Tumors Replicate Human Tumors and Vary in Survival and Nuclear Grade Based on Anatomical Location. Plos One. 2014 July, Vol. 9, Issue 7 e102409.
  176. Faina Linkov, Lauren Kokai, Robert Edwards, M. Aamir Sheikh, Kle E. Freese, Kacey G. Marra & J. Peter Rubin. The role of adipose-derived stem cells in endometrial cancer proliferation. Scandinavian Journal of Clinical & Laboratory Investigation, 2014; 74 (Suppl 244): 54-58.
  177. Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, Morris RT, Akerley WL, Holloway RW, Method MW, Plaxe SC, Walker JL, Friccius-Quecke H, Krasner CN. Catumaxomab for the Treatment of Malignant Ascites in Patients with Chemotherapy-Refractory Ovarian Cancer: A Phase II Study. Int J Gynecol Cancer. 2014 Sept 24. [Epub ahead of print] PMID: 25254563

Abstracts Published

  1. Edwards RP, McCallister D, Kulhavy L, Storkus W, Crowley-Nowick PA. Characterization of tumor infiltrating lymphocytes isolated from early and advanced staged ovarian cancer. J Soc Gynecol Invest 3:380A, 1996.
  2. Kelley JL, Kridgen P, Downs L, Guzick D, Karasek K, Kunschner AJ, Price FV, and Edwards RP. Postoperative treatment of invasive cervical carcinoma found after simple hysterectomy.  Gynecologic Oncology 60:141, 1996.
  3. Edwards RP, Gooding W, Lembersky BC, Kunschner AJ, Seski JC, et al. Surgicopathologic factors associated with prolonged survival after intraperitoneal interleukin-2. Gynecologic Oncology 60:128, 1996.
  4. Kowalski LD, Kanbour AI, Kanbour-Shakir A, Kunschner AJ, Kelley JL, Burnham J, Price FV, and Edwards RP. A case-matched molecular comparison of extraovarian vs primary ovarian adenocarcinoma. Gynecologic Oncology 60:167, 1996.
  5. Edwards RP, Maimone L, Kelley JK, Price FV, Kunschner AJ and English DH. The impact of clinical pathway in resource utilization for radical hysterectomy. Gynecologic Oncology 60:124, 1996.
  6. Edwards RP, Gooding W, Lembersky BC, Colonello K, Hammond R, Paradise C, Kowal CD, Kunschner AJ, Baldisseri M, Kirkwood JM, Herberman RB. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: 24-hour versus 7-day infusion. Journal of Clinical Oncology, Nov 1, 1997: 3399-3407.
  7. Crowley-Nowick PA, Bowman FP, Colonello K, etc. Cytokine concentration in cervical secretions throughout the menstrual cycle. J Soc for Gynecol Invest 5:90A, 1998.
  8. Black CA, Edwards RP. IgG transport through the vagina and ectocervix via exfoliative transcytosis. J Soc for Gynecol Invest 5:53A, 1998.
  9. Edwards RP, Gooding W, Colonello K, Price FV, Kelley JL, Jacob HE, Lotze M, and Herberman RB. Outpatient infusion of intraperitoneal interleukin-2 (IP IL-2) is safe and active for persistent ovarian cancer after Taxol and Platinum. Society of Gynecologic Oncologists 29th Annual Meeting, February 7-11, 1998, Orlando, Florida.
  10. Morrissey TP, Edwards RP, Gooding W, Crowley-Nowick PA, Black CA, Colonello KA, Kelley JL, Price FV, Kunchner AJ, Elder EM, Whiteside TL, and Herberman RB. Intraperitoneal interleukin-2 (IP IL-2) is active in persistent ovarian cancer after Platinum/Paclitaxel Chemotherapy. Society of Gynecologic Oncologists 31st Annual Meeting, February 5-9, 2000, San Diego, CA.
  11. Sit AS, Edwards RP, Kelley JL, Comerci JT, and Kunschner AJ. Paclitaxel and Carboplatin Combination Chemotherapy in Malignant Mixed Mullerian Tumors of the Ovary. Society of Gynecologic Oncologists 31st Annual Meeting, February 5-9, 2000, San Diego, CA.
  12. Edwards RP, Comerci JT, Kanbour-Shakir A, Sumkin J, Makhija S, Colonello K, Cost M, Rohan L. Identification of the Sentinel Node in Cervix Cancer. Gynecologic Oncology 80:305-306, 2001.
  13. Lokshin AE, Edwards RP. Death Ligand TRAIL Synergizes with Low-Dose Cisplatin in Inducing Antitumor Activity in Ovarian Cancer Cell Lines. Presented at the Annual Meeting of the Society of Gynecologic Oncologists, Nashville, TN, March 3-7, 2001.
  14. Comerci JT, Sloan C, Edwards RP, Makhija S, Krohn M, Hatem F. Cyclooxygenase-2 Expression in Normal Endometrium, Endometrial Hyperplasia, and Carcinoma. Gynecologic Oncology 80:303, 2001.
  15. Sukumvanich P, Cost M, Deal K, Makhija S, Edwards RP, Comerci JT. Cyclooxygenase-2 Expression in Normal Cervical Epithelium and Cervical Neoplasm. Gynecologic Oncology 80:290-291, 2001.
  16. Makhija S, Sit A, Edwards RP, Kanbour-Shakir A, Godrey T. Identification of genetic alterations responsible for chemoresistance in epithelial ovarian cancer. Journal of the Society of Gynecologic Investigation 8:53A, 2001.
  17. Sit AS, Godfrey T, Edwards R, Comerci JT, Aufman K, Makhija S. A case-matched comparison of molecular alterations in mixed mesodermal mullerian tumors of the ovary and epithelial ovarian carcinoma. American Association for Cancer Research 42:51, 2001.
  18. Makhija SK, Sit A, Edwards R, Comcerci JT, Aufman K, Kanbour-Shakir A, Godfrey T. Identification of genetic alterations responsible for chemoresistance in epithelial ovarian cancer. American Association for Cancer Research 42:64, 2001.
  19. Comerci JT, Sloan C, Edwards RP, Makhija S, Krohn MJ, Hatem F. Cyclooxygenase-2 expression win normal endometrium, endometrial hyperplasia and carcinoma. American Association for Cancer Research 42:17, 2001.
  20. Makhija S, Howden N, Comerci J, Kelley, J, Kunschner A, Meltzer C, Sumkin J, Edwards R. PET/CT imaging for the detection of recurrent ovarian and fallopian tube cancer: A retrospective review. American Association for Cancer Research 42:51, 2001.
  21. Sit ASY, Kunschner AJ, Kelley JL, Comerci JT, Makhija S, Edwards RP. Paclitaxel and carboplatin combination chemotherapy in recurrent or persistent cervical carcinoma. American Society of Clinical Oncology 20:210a, 2001.
  22. Heron DE, Gerszten K, Comerci JT, Gallion H, Edwards RP, King G, Selvaraj R, Wu A. 3D
    • conformal vs. intensity modulated radiotherapy (MRT) for the adjuvant treatment of gynecologic malignancies: A comparative study of dose-volume histograms (DVHs). Society of Gynecologic Oncologists, Miami Beach, FL, March 2002.
  23. Gordon AN, Stringer A, Edwards RP, Whiteside TL, Fingert HJ, Schultes BC. Clinical and immunologic outcomes of patients (Pts) with recurrent epithelial ovarian cancer (EOC) treated with OvarexAE Mab (Ov) and chemotherapy (Ct). Society of Gynecologic Oncologists, Miami Beach, FL, March 2002.
  24. Posluszny DM, Edwards RP, Comerci JT, McFeeley S, Slater BL, Knapp JA, Baum A. Quantitation of the psychological trauma in women newly-diagnosed with gynecologic cancer. Society of Gynecologic Oncologists, Miami Beach, FL, March 2002.
  25. Sassi RR, Edwards RP, Marrangoni AM, Lokshin AE. Mechanisms of acquired resistance to combined trail/cisplatin treatment in ovarian cancer. American Association for Cancer Research, San Francisco, CA, April 2002.
  26. Schultes BC, Gordon A, Ehlen T, Nicodemus CF, Fingert H, Edwards RP, Whiteside TL. Induction of tumor- and CA125- specific T cell responses in patients (PTS) with epithelial ovarian cancer (EOC) treated with Ovarexâ MAB-B43.13. American Association for Cancer Research, San Francisco, CA, April 2002.
  27. Gold MA, Huh WK, Cestero RM, Garcia FA, Guido RM, Alvarez RD, McIntyre-Seltman K, De Santis T, Harper DM, Sundborg M, Holschneider C, Blank S, Edwards RP, Felix JC, Ferris DG, Walker JL. Optical detection of cervical neoplasia: Results from a randomized, dual-arm, multi-center clinical trial. Society of Gynecologic Oncologists, San Diego, California, February 2004. (Gynecol Oncol 2004;92:397-398)
  28. Randall-Whitis L, Helm CW, Toler CR, Martin RS, Metzinger DS, Edwards RP. Secondary surgical cytoreduction and hyperthermic intraperitoneal chemoperfusion (SSC-HIPEC) for recurrent gynecologic malignancies. American Society for Clinical Oncology, New Orleans, Louisiana, June 2004. (ASCO Annual Meeting Proceedings 2004;23:471)
  29. Helm CW, Martin III RS, Metzinger DS, Edwards RP. Secondary surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (SSC-HIPEC) for recurrent ovarian and endometrial cancer. International Gynecologic Cancer Society, Edinburgh, October 2004. (International Journal of Gynecological Cancer, Vol. 14, Suppl. 1, 2004:167)
  30. Draper J, Helm CW, Edwards RP, Metzinger DS, Taylor DD. A prospective investigation of tumor membrane fragments in the differentiation of benign and malignant adnexal masses prior to surgery. (ASCO Annual Meeting Proceedings June 1, 2005: 5112).
  31. Gordon A, Schultes B, Gallion H, Edwards RP, Whiteside T, Cermak J, Nicodemus C. CA-125 and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecologic Oncology 94 (2004) 340-351.
  32. Huh WK, Gold MA, Walker JL, Garcia FA, Cestero RM, Harper DM, Guido RM, McIntyre-Seltman K, Sundborg M, Holschneider C, Blank S, Edwards R, De Santis T, Ferris DG, Felix JC, Alvarez RD. Optical detection of cervical neoplasia: Final results from a randomized, dual-arm, multi-center clinical trial. International Gynecologic Cancer Society, Edinburgh, October 2004. (International Journal of Gynecological Cancer, Vol. 14, Suppl. 1, 2004:12)
  33. Heron DE, Axtell A, Gerszten K, Amortegui A, Kelley J, Comerci J, and Edwards RP. Villoglandular adenocarcinoma of the cervix recurrent in an episiotomy scar: A case report in a 32-year-old female. International Journal of Gynecologic Cancer 15:366-371, 2005.
  34. Beriwal S, Jain S, Heron D, Kim H, Gerszten K, Kelley JL, Edwards RP. Clinical outcomes with adjuvant treatment of endometrial carcinoma using intensity-modulated radiation therapy. Gynecology Oncology Vol 101, #1, Supplement 1, April 2006.
  35. Gallion H, Nickles-Fader A, Kelley JL, Edwards RP, Comerci JC, Hosford SL, Schelhas HF. ChemoFx assay is an independent predictor of response to platinum-based chemotherapy in primary ovarian cancer. Gynecology Oncology Vol 101, #1, Supplement 1, April 2006.
  36. Nickles-Fader A, Rohan L, Cost M, Comerci JC, Kelley JL, Sukumvanich P, Schwartz B, Kanbour-Shakir A, Sumkin J, Edwards RP. Intraoperative sentinel node detection using technetium-99m sulvur colloid predicts nodal metastases in patients with early-stage cervical cancer. Gynecology Oncology Vol 101, #1, Supplement 1, April 2006.
  37. Helm CW, Metzinger D, Parker L, Gordnier M, Edwards RP, Martin III R, Graham J. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for recurrent ovarian carcinoma. Gynecology Oncology Vol 101, #1, Supplement 1, April 2006.
  38. Edwards RP, Studts J, Okeke R, Jenson B, Clark L, Helm CW, Metzinger D, O’Connor D, Bowling S, Moore G, Miller D. Human Papillomavirus self-testing is preferred by women with cervical neoplasia. Gynecology Oncology Vol 101, #1, Supplement 1, April 2006.
  39. Bolton KL, Tyrer J, Song H., Ramus SJ, Notaridou M, Jones C, Shet T, Gentry Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Edwards, RP, Odunski, K, etc. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genert. 2010 Oct;42(10):880-4. Epub 2010 Sep 19. PMID: 20852633
  40. Teng PN, Rungruang BJ, Hood BL, Sun M, Flint MS, Bateman NW, Dhir, R, Bhargava R, Richard SD, Edwards RP, Conrads TP. Assessment of buffer systems for harvesting proteins from tissue interstitial fluid for proteomic analysis. J. Proteome Res. 2010 Aug 6;9(8):4161-9. PMID 20518575.
  41. Ness RB, Dodge RC, Edwards RP, Baker JA, Moysich KB. Contraception methods, beyond oral contraceptives and tubal ligation, and risk of ovarian cancer. Ann Epidemiol. 2011 Mar; 21(3):188-96 Epub 2010 Dec. 15. PMID: 21109450 (Pub Med in process)
  42. Monk BJ, Sill MW, Hanjani P, Edwards R., Rotmensch J, DeGeest K, Bonebrake AJ, Walker JL. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of Gynecologic Oncology Group. PMID:21144560 (Pub Med – in process)Gynecol Oncol. 2011 Mar;120(3):459-63. Epub 2010 Dec 7.

Manuscript Reviews

  1. Release of tumor necrosis factor, Interleukin-1, and their inhibitors by isolated lymphoid and tumor cell populations from human ovarian carcinoma. Cancer Research, 1993.
  2. Insulin-like growth factors (IGF) and transformation of normal smooth muscle cells to leiomyosarcomas. Dutch Cancer Society, 1994.
  3. Increased natural killer cell activity in uterine cervix cancer patients undergoing radiation therapy. Natural Immunity, 1995.
  4. Absence of papillomavirus DNA in normal tissue adjacent to most cervical intraepithelial neoplasms. Obstetrics & Gynecology, 1995.
  5. Investigation of immunoselection-induced morphological and immunochemical changes in ovarian carcinoma cells. Gynecologic Oncology, 1995.
  6. Current results of pelvic perfusion for non resectable or relapsing pelvic cancer. The Cancer Journal, 1995.
  7. Pelvic hematoma following angiography: Another cause of elevated serum CA-125. Obstetrics & Gynecology, 1996.
  8. Laparoscopic lateral ovarian transposition before pelvic irradiation for a non Hodgin lymphoma: A case report. Gynecologic Oncology, 1998.
  9. Low risk of perinatal transmission of HPV: Results from a prospective cohort study. JAMA Women’s Health Information Center, 1998.
  10. Arterial occlusion following surgery for an ovarian malignancy. Obstetrics & Gynecology, 1998.
  11. Cervical cancer is unlikely to express MHC class II. International Journal of Cancer, 1998.
  12. Interferon-Gamma in the first-line therapy of ovarian cancer: A randomized phase III trial. Journal of Clinical Oncology, 1999.
  13. In vitro adoptive cellular immunotherapy of human ovarian cells with peritoneal macrophages activated with IFNy, LPS and IL2. Gynecologic Oncology, 1999.
  14. Ovarian cancer risk assessment: The role of primary care physician. Obstetrics & Gynecology, 1999.
  15. Phase II study of two dose levels of Toremifene in the treatment of chemotherapy-resistant papillary carcinoma of the ovary.  National Cancer Institute, PDQ, 1999.
  16. Soluable member(s) of the mesothelin/MPF family detectable in sera from patients with ovarian cancer.  PNAS, 1999.
  17. Surface expression of major histocompatibility complex (MHC) class I in human squamous cervical cancer is not down regulated as compared to normal cervices: An immuno electronmicroscopical study. Cancer, 1999.
  18. p53 codon 72 polymorphism and risk of cervical cancer in Mexico. Obstetrics & Gynecology, 2001.
  19. Invasive vulvar squamous cell carcinoma in young women: A Clinicopathologic study of 21 cases.   Gynecologic Oncology, 2001.
  20. Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecologic Oncology, 2002.
  21. A comprehensive review of liver masses in pregnancy and a proposed algorithm for their diagnosis and management. The American Journal of Surgery, 2003.
  22. Current status of sentinel lymph node biopsy for cervical cancer. The American Journal of Surgery, 2003.
  23. Ethical issues in fertility preservation for adolescent cancer survivors: Oocyte & ovarian tissue cryopreservation. Journal of Pediatric & Adolescent Gynecology, 2003.
  24. Sp17-pulsed dendritic cell vaccine for advanced Sp17+ cancer. Journal of Immunotherapy, December 2003.
  25. Factor V Leiden mutation in patients with breast cancer with a central venous catheter: Risk of deep vein thrombosis. Supportive Cancer Therapy, March 2005.
  26. Anaplastic Carcinoma Arising in an Ovarian Mucinous Cystadenocarcinoma in a 17-year-old Female. Journal of Pediatric & Adolescent Gynecology, 2005.
  27. Immunohistochemical analysis of CD4+ and CD8+ T-cell sublets in high risk human papilllomavirus-associated pre-malignant and malignant lesions of the uterine cervix. Gynecologic Oncology, 2005.
  28. Expression of the transcriptional co-regulator FHL2 in human breast cancer: a clinico=pathologic study. Journal of the Society for Gynecologic Investigation, 2005.
  29. Molecular Construction and Characterization of a Novel Exotoxin Fusion Protein that Selectively Blocks the B7:CD28 Costimulatory Signal System. Journal of Immunology, December 2005.
  30. Cytokines, GM-CSF and IFN-gamma Administered by Priming and Post-Chemotherapy Cycling in Recurrent Ovarian Cancer Patients Receiving Carboplatin. Journal of Translational Medicine, January 2006.
  31.  A case of small cell carcinoma of the endometrium for which combination chemotherapy consisting of paclitaxel and Carboplatin was not effective. Gynecologic Oncology, March 2006.
  32. The influence of surgery on serum levels of IL-10, CRP and skin reactivity to Histamine and Amthamine in gynecological cancer patients. Journal of Immunology, August 2006.
  33. Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer.
  34. Cervical dysplasia among women over 35 years of age. The American Journal of Obstetrics & Gynecology, August 2007.
  35. Vlad AM, Kettel JC, Edwards RP, and Finn OJ. Mucin 1 (MUC1) glycoprotein modulates the ability of activated T cells to adhere to endothelia through increased binding to ICAM-1 and decreased adhesion to E-selection. Submitted, under review, Journal of Leukocyte Biology (2008).
  36. Budiu R, Diaconu I, Chrissluis R, Dricu A, Edwards RP, Finn OHJ, Vlad AM. Mice progressing to human mucin 1 (Muc1)-positive ovarian endometriosis-like lesions develop anti-Muc1 antibodies and show increased Foxp2 positive T cells in regional lymph nodes. Submitted, under review, Disease Models and Mechanisms (2008).
  37. Vlad AM, Budiu R, Thaller J, Finn OJ, Edwards, RP. Immune monitoring of ovarian cancer patients treated with intraperitoneal IL-2 shows correlations of serum anti-MUC1 antibodies. Submitted, under review, Journal of Clinical Oncology (2009).
  38. “Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1-1cm after secondary cytoreduction”. Journal of Surgical Oncology (2009).
  39. “Ovarian Cancer”. eMedicine (2009).
  40. “Efficacy of a 9-Valent HPV Vaccine against Genital Infection and Intraepithelial Neoplasia in Women” New England Journal of Medicine (2014).

Robert P. Edwards

Professor and Director

 

  • :(412) 641-5418
  • DEPARTMENTTransformational Medicine
    Magee Women’s Hospital
  • COUNTRYUSA